Thomas Leggett Sells 2,196 Shares of Stoke Therapeutics (NASDAQ:STOK) Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) CFO Thomas Leggett sold 2,196 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $33.01, for a total value of $72,489.96. Following the sale, the chief financial officer owned 12,554 shares in the company, valued at $414,407.54. The trade was a 14.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Thomas Leggett also recently made the following trade(s):

• On Wednesday, March 18th, Thomas Leggett sold 2,382 shares of Stoke Therapeutics stock. The stock was sold at an average price of $31.34, for a total value of $74,651.88.

Stoke Therapeutics Trading Up 1.0%

Shares of STOK opened at $33.51 on Friday. Stoke Therapeutics, Inc. has a 52 week low of $5.35 and a 52 week high of $40.22. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of 50.01 and a beta of 1.07. The stock has a 50 day moving average of $32.61 and a 200-day moving average of $30.02.

Trending Headlines about Stoke Therapeutics

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Canaccord raised its price target sharply to $60 and assigned a Buy, giving STOK a meaningful upside projection versus recent levels — a clear catalyst for buying interest. Canaccord raises STOK price target to $60 (Benzinga)
• Positive Sentiment: Other analysts reiterated/raised Buy views and targets (BTIG reaffirmed Buy with a $39 target; Wedbush pushed its target to $38; Needham published a bullish outlook), adding breadth to the bullish narrative and likely attracting momentum and institutional buyers. BTIG reaffirmation (Benzinga) Wedbush boosts price target to $38 (AmericanBankingNews) Needham bullish outlook (AmericanBankingNews)
• Positive Sentiment: Coverage of Stoke’s STK‑001 program emphasizes potential beyond seizure reduction (aiming to restore developmental loss in Dravet syndrome), supporting longer‑term upside expectations if clinical data meet endpoints. FierceBiotech: Stoke aims to restore developmental loss in Dravet syndrome
• Neutral Sentiment: Analysis pieces reviewed a recent sharp pullback and what triggered it—useful context for traders but not a new company catalyst. Kalkine: What triggered the sudden drop?
• Neutral Sentiment: Technical/volume note — today’s volume is well above average and the stock is trading above both its 50‑ and 200‑day SMAs, indicating higher investor interest; this can amplify moves in either direction.
• Negative Sentiment: Significant insider selling: multiple executives (including the CFO, general counsel and senior insiders such as Barry Ticho) disclosed sizable sales across March 17–19, which can weigh on sentiment and prompt investor caution despite analyst optimism. Representative SEC filings: SEC Form 4 (Jonathan Allan) SEC Form 4 (Barry Ticho)

Institutional Investors Weigh In On Stoke Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its position in Stoke Therapeutics by 1.2% in the fourth quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock worth $935,000 after buying an additional 354 shares during the period. Strs Ohio grew its position in shares of Stoke Therapeutics by 9.4% during the fourth quarter. Strs Ohio now owns 7,000 shares of the company’s stock worth $222,000 after acquiring an additional 600 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares during the last quarter. Generali Investments Management Co LLC increased its holdings in shares of Stoke Therapeutics by 41.0% in the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock worth $78,000 after acquiring an additional 718 shares during the period. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Stoke Therapeutics in the 4th quarter worth about $26,000.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Wall Street Zen lowered shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Chardan Capital restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a report on Monday, December 29th. Wedbush boosted their price objective on shares of Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research note on Monday, December 15th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $41.83.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.